Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab

European Journal of Cancer

Volumn 64, Issue , 2016, Pages 116-126

  Wistuba Hamprecht, Kilian ^a   Martens, Alexander ^a   Haehnel, Karin ^a   Geukes Foppen, Marnix ^b   Yuan, Jianda ^c   Postow, Michael A ^c,d   Wong, Phillip ^c   Romano, Emanuela ^e   Khammari, Amir ^f   Dreno, Brigitte ^f   Capone, Mariaelena ^g   Ascierto, Paolo A ^g   Demuth, Ilja ^h   Steinhagen Thiessen, Elisabeth ^h   Larbi, Anis ⁱ   Schilling, Bastian ^j,k   Schadendorf, Dirk ^j,k   Wolchok, Jedd D ^c,d   Blank, Christian U ^b   Pawelec, Graham ^a,l,m   Garbe, Claus ^a   Weide, Benjamin ^a   more..

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e PSL RESEARCH UNIVERSITY   (France)

^f INSERM   (France)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ AGENCY FOR SCIENCE   (Singapore)

^j UNIVERSITY HOSPITAL ESSEN   (Germany)

^k GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^l NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^m KING'S COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Biomarker; Immunotherapy; Ipilimumab; Melanoma; Survival; T cells

Indexed keywords

IPILIMUMAB; LACTATE DEHYDROGENASE; ANTINEOPLASTIC AGENT; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GAMMA DELTA T LYMPHOCYTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE; BLOOD; CASE CONTROL STUDY; CELL DIFFERENTIATION; CYTOLOGY; IMMUNOLOGY; IMMUNOTHERAPY; MIDDLE AGED; PROCEDURES; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS;

EID: 84977633907     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.06.001     Document Type: Article

References (49)

1. [1] Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:26 (2011), 2517–2526.
2. [2] Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:8 (2010), 711–723.
3. [3] Schadendorf, D., Hodi, F.S., Robert, C., Weber, J.S., Margolin, K., Hamid, O., et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33:17 (2015), 1889–1894.
4. [4] Kelderman, S., Heemskerk, B., van Tinteren, H., van den Brom, R.R., Hospers, G.A., van den Eertwegh, A.J., et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 63:5 (2014), 449–458.
5. [5] Delyon, J., Mateus, C., Lefeuvre, D., Lanoy, E., Zitvogel, L., Chaput, N., et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 24:6 (2013), 1697–1703.
6. [6] Di Giacomo, A.M., Danielli, R., Calabro, L., Bertocci, E., Nannicini, C., Giannarelli, D., et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother 60:4 (2011), 467–477.
7. [7] Martens, A., Wistuba-Hamprecht, K., Geukes Foppen, M.H., Yuan, J., Postow, M.A., Wong, P., et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res 22 (2016), 2908–2918.
8. [8] Meyer, C., Cagnon, L., Costa-Nunes, C.M., Baumgaertner, P., Montandon, N., Leyvraz, L., et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 63:3 (2014), 247–257.
9. [9] Weide, B., Martens, A., Zelba, H., Stutz, C., Derhovanessian, E., Di Giacomo, A.M., et al. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res 20:6 (2014), 1601–1609.
10. [10] Weide, B., Zelba, H., Derhovanessian, E., Pflugfelder, A., Eigentler, T.K., Di Giacomo, A.M., et al. Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol 30:15 (2012), 1835–1841.
11. [11] Braumuller, H., Wieder, T., Brenner, E., Assmann, S., Hahn, M., Alkhaled, M., et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 494:7437 (2013), 361–365.
12. [12] Kvistborg, P., Shu, C.J., Heemskerk, B., Fankhauser, M., Thrue, C.A., Toebes, M., et al. TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology 1:4 (2012), 409–418.
13. [13] Holtmeier, W., Kabelitz, D., Gammadelta T cells link innate and adaptive immune responses. Chem Immunol Allergy 86 (2005), 151–183.
14. [14] Vantourout, P., Hayday, A., Six-of-the-best: unique contributions of gammadelta T cells to immunology. Nat Rev Immunol 13:2 (2013), 88–100.
15. [15] Porcelli, S., Brenner, M.B., Band, H., Biology of the human gamma delta T-cell receptor. Immunol Rev 120 (1991), 137–183.
16. [16] Chien, Y.H., Meyer, C., Bonneville, M., Gammadelta T cells: first line of defense and beyond. Annu Rev Immunol 32 (2014), 121–155.
17. [17] Wistuba-Hamprecht, K., Haehnel, K., Janssen, N., Demuth, I., Pawelec, G., Peripheral blood T-cell signatures from high-resolution immune phenotyping of gammadelta and alphabeta T-cells in younger and older subjects in the Berlin Aging Study II. Immun Ageing, 12, 2015, 25.
18. [18] Dechanet, J., Merville, P., Berge, F., Bone-Mane, G., Taupin, J.L., Michel, P., et al. Major expansion of gammadelta T lymphocytes following cytomegalovirus infection in kidney allograft recipients. J Infect Dis 179:1 (1999), 1–8.
19. [19] Silva-Santos, B., Serre, K., Norell, H., Gammadelta T cells in cancer. Nat Rev Immunol 15:11 (2015), 683–691.
20. [20] Hayday, A.C., [Gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 18 (2000), 975–1026.
21. [21] Kobayashi, H., Tanaka, Y., Gammadelta T cell immunotherapy-a review. Pharm (Basel) 8:1 (2015), 40–61.
22. [22] Gober, H.J., Kistowska, M., Angman, L., Jeno, P., Mori, L., De Libero, G., Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 197:2 (2003), 163–168.
23. [23] Kabelitz, D., Kalyan, S., Oberg, H.H., Wesch, D., Human Vdelta2 versus non-Vdelta2 gammadelta T cells in antitumor immunity. Oncoimmunology, 2(3), 2013, e23304.
24. [24] Wilhelm, M., Kunzmann, V., Eckstein, S., Reimer, P., Weissinger, F., Ruediger, T., et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102:1 (2003), 200–206.
25. [25] Dieli, F., Vermijlen, D., Fulfaro, F., Caccamo, N., Meraviglia, S., Cicero, G., et al. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67:15 (2007), 7450–7457.
26. [26] Kobayashi, H., Tanaka, Y., Yagi, J., Osaka, Y., Nakazawa, H., Uchiyama, T., et al. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 56:4 (2007), 469–476.
27. [27] Yazdi, A.S., Morstedt, K., Puchta, U., Ghoreschi, K., Flaig, M.J., Rocken, M., et al. Heterogeneity of T-cell clones infiltrating primary malignant melanomas. J Invest Dermatol 126:2 (2006), 393–398.
28. [28] Argentati, K., Re, F., Serresi, S., Tucci, M.G., Bartozzi, B., Bernardini, G., et al. Reduced number and impaired function of circulating gamma delta T cells in patients with cutaneous primary melanoma. J Invest Dermatol 120:5 (2003), 829–834.
29. [29] Petrini, I., Pacini, S., Galimberti, S., Taddei, M.R., Romanini, A., Petrini, M., Impaired function of gamma-delta lymphocytes in melanoma patients. Eur J Clin Invest 41:11 (2011), 1186–1194.
30. [30] Campillo, J.A., Martinez-Escribano, J.A., Minguela, A., Lopez-Alvarez, R., Marin, L.A., Garcia-Alonso, A.M., et al. Increased number of cytotoxic CD3+ CD28− gammadelta T cells in peripheral blood of patients with cutaneous malignant melanoma. Dermatology 214:4 (2007), 283–288.
31. [31] Wistuba-Hamprecht, K., Di Benedetto, S., Schilling, B., Sucker, A., Schadendorf, D., Garbe, C., et al. Phenotypic characterization and prognostic impact of circulating gammadelta and alphabeta T-cells in metastatic malignant melanoma. Int J Cancer 138:3 (2016), 698–704.
32. [32] Bialasiewicz, A.A., Ma, J.X., Richard, G., Alpha/beta- and gamma/delta TCR(+) lymphocyte infiltration in necrotising choroidal melanomas. Br J Ophthalmol 83:9 (1999), 1069–1073.
33. [33] Wolchok, J.D., Hoos, A., O'Day, S., Weber, J.S., Hamid, O., Lebbe, C., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:23 (2009), 7412–7420.
34. [34] Martens, A., Wistuba-Hamprecht, K., Yuan, J., Postow, M.A., Wong, P., Capone, M., et al. Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab. Clin Cancer Res, 2016 [Epub ahead of print].
35. [35] Bertram, L., Bockenhoff, A., Demuth, I., Duzel, S., Eckardt, R., Li, S.C., et al. Cohort profile: the Berlin Aging Study II (BASE-II). Int J Epidemiol 43:3 (2014), 703–712.
36. [36] Wistuba-Hamprecht, K., Pawelec, G., Derhovanessian, E., OMIP-020: phenotypic characterization of human gammadelta T-cells by multicolor flow cytometry. Cytom A 85:6 (2014), 522–524.
37. [37] Balch, C.M., Gershenwald, J.E., Soong, S.J., Thompson, J.F., Atkins, M.B., Byrd, D.R., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:36 (2009), 6199–6206.
38. [38] Himoudi, N., Morgenstern, D.A., Yan, M., Vernay, B., Saraiva, L., Wu, Y., et al. Human gammadelta T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells. J Immunol 188:4 (2012), 1708–1716.
39. [39] Muto, M., Baghdadi, M., Maekawa, R., Wada, H., Seino, K., Myeloid molecular characteristics of human gammadelta T cells support their acquisition of tumor antigen-presenting capacity. Cancer Immunol Immunother 64:8 (2015), 941–949.
40. [40] Wesch, D., Peters, C., Siegers, G.M., Human gamma delta T regulatory cells in cancer: fact or fiction?. Front Immunol, 5, 2014, 598.
41. [41] Peters, C., Oberg, H.H., Kabelitz, D., Wesch, D., Phenotype and regulation of immunosuppressive Vdelta2-expressing gammadelta T cells. Cell Mol Life Sci 71:10 (2014), 1943–1960.
42. [42] Thedrez, A., Sabourin, C., Gertner, J., Devilder, M.C., Allain-Maillet, S., Fournie, J.J., et al. Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue?. Immunol Rev 215 (2007), 123–135.
43. [43] Tan, Crystal Tze Ying, Wistuba-Hamprecht, Kilian, Xu, Weili, Nyunt, Ma Schwe Zin, Vasudev, Anusha, Lee, Bernett Teck Kwong, et al. Vδ2+ and α/β T cells show divergent trajectories during human aging. Oncotarget, 2016 (in press) Published June 15, 2016. http://dx.doi.org/10.18632/oncotarget.10096.
44. [44] Kabelitz, D., Dechanet-Merville, J., Editorial: “Recent advances in gamma/delta T cell biology: new Ligands, new functions, and new Translational perspectives”. Front Immunol, 6, 2015, 371.
45. [45] Coffelt, S.B., Kersten, K., Doornebal, C.W., Weiden, J., Vrijland, K., Hau, C.S., et al. IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522:7556 (2015), 345–348.
46. [46] Wu, P., Wu, D., Ni, C., Ye, J., Chen, W., Hu, G., et al. gammadeltaT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 40:5 (2014), 785–800.
47. [47] Lafont, V., Sanchez, F., Laprevotte, E., Michaud, H.A., Gros, L., Eliaou, J.F., et al. Plasticity of gammadelta T Cells: impact on the anti-tumor response. Front Immunol, 5, 2014, 622.
48. [48] Iwasaki, M., Tanaka, Y., Kobayashi, H., Murata-Hirai, K., Miyabe, H., Sugie, T., et al. Expression and function of PD-1 in human gammadelta T cells that recognize phosphoantigens. Eur J Immunol 41:2 (2011), 345–355.
49. [49] Kunzmann, V., Smetak, M., Kimmel, B., Weigang-Koehler, K., Goebeler, M., Birkmann, J., et al. Tumor-promoting versus tumor-antagonizing roles of gammadelta T cells in cancer immunotherapy: results from a prospective phase I/II trial. J Immunother 35:2 (2012), 205–213.